Phase 1 N=117 A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject
Healthy
Primary: Skin Irritation Score of the Application Site — 0.237; 0.289; 0.250 Scores on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=472 Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
Gastrointestinal Stromal Tumors
Primary: Number of Participants With Treatment-Related Adverse Events — 450 Participants
N/A N=87 ReActiv8 Post Market Surveillance Registry
Chronic Low Back Pain
Primary: Low Back Pain - Numeric Pain Rating (NRS) Scale — 4.5; 4.3; 3.8; 3.4 units on a scale
N/A N=451 Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin
Breast Neoplasms
Primary: Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane — 126; 324; 372; 68 participants
N/A N=30 RHA® Redensity With New Anesthetic Agent - Perioral Rhytids
Aging · Pain
Primary: Non-inferiority of RHA® Redensity With New Anesthetic Agent Versus RHA® Redensity With Lidocaine in Terms of Reducing Pain During Device Injection Into the Upper…
N/A N=7,740 Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
N/A N=3 Safety And Efficacy Of Rescriptor In Patients For Human Immunodeficiency Virus (HIV) Patients
HIV-1 Infection
Primary: Number of Participants Who Reported Unlisted Adverse Drug Reaction. — 0 participants
N/A N=30 RHA® 4 With New Anesthetic - Nasolabial Folds
Aging · Pain
Primary: Non-inferiority of RHA® 4 With New Anesthetic Agent Versus RHA® 4-Lidocaine in Terms of Reducing Pain During Device Injection Into Nasolabial Folds. — 17.1; 16.3 mm…
N/A N=19 The Adverse Drug Reaction (ADRe) Profile for Polypharmacy
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
N/A N=3,337 Special Investigation For Long-Term Use Of Sildenafil (Regulatory Post Marketing Commitment Plan)
Pulmonary Hypertension
Primary: Number of Participants With Treatment-Related Adverse Events — 448; 101 Participants
N/A N=2,860 Methotrexate (Rheumatrex) High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)
Arthritis · Rheumatoid · High Dose
Primary: Number of Participants With Treatment-Related Adverse Events — 608 Participants
N/A N=68 Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)
CCR5-tropic HIV-1 Infection
Primary: Percentage of Participants With Adverse Drug Reactions (ADRs) — 23.53 percentage of participants
N/A N=909 Long Term Use of Somatropin in Patients Small for Gestational Age
Small for Gestational Age
Primary: Number of Participants With Treatment Related Adverse Events. — 44 participants
Phase 4 N=220 Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
Relapsing-remitting Multiple Sclerosis
Primary: Percentage of the Sites Developing a Injection Site Reaction (ISR) Reported by Participants 24 Hours After Each Injection — 31; 37 Percentage of sites
N/A N=251 Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
Acromegaly
Primary: Number of Participants With Treatment-Related Adverse Events — 89; 20 Participants
Early Phase 1 N=25 Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
Melanoma
Primary: Number of Participants With Treatment-related Adverse Events as a Measure of Safety and Tolerability — 1; 0; 4; 2 participants
N/A N=982 Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration -
Pneumonia · Lung Abscess · Peritonitis
Primary: Number of Participants With Treatment-Related Adverse Events — 96 Participants
N/A N=1,674 Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
Carcinoma, Renal Cell
Primary: Number of Participants With Treatment-Related Adverse Events — 1599 Participants
Phase 2 N=686 COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…
N/A N=72 Safety Evaluation of Aline HA, an Implanted Cross-Linked HA Device
Disorder of Soft Tissue
Primary: Assessment of Treatment Site Responses Post Procedure — 78 percentage of participants with any AE
Phase 3 N=120 Methotrexate-Inadequate Response Autoinjector Device Sub Study
Rheumatoid Arthritis
Primary: Pharmacokinetic (PK) Analysis: Adjusted Geometric Mean Observed Serum Trough Concentration at Steady State (Cminss) of Abatacept Using a Prefilled Syringe (Measured on…
Phase 4 N=687 Post Marketing Surveillance for ADACEL™ in South Korea
Diphtheria · Tetanus · Pertussis
Primary: Summary of Adverse Events Reported in Participants That Received a Single Intramuscular Dose of Adacel™ — 168; 1; 68 Participants
N/A N=14 RAL-eve Study: Raltegravir Substitution Study
HIV Infections
Primary: The Percentage of Patients Who Maintain a Viral Load < 50 Copies/ml After Being Switched From Enfuvirtide to Raltegravir — 86 percentage
Phase 3 N=104 Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Pancreatectomy for Chronic Pancreatitis
Primary: Percentage of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 365±14 Days After Transplant. — 20.0; 21.2 Percentage of participants…
Phase 4 N=6,983 World-wide Randomized Antibiotic Envelope Infection Prevention Trial
CIED Related Infection
Primary: 12 Month Kaplan-Meier Estimate of Major CIED Infection Rate — 0.7; 1.2 Percentage of subjects — p=0.0406
N/A N=332 Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian Infants
Infections, Rotavirus
Primary: Number of Subjects Reporting Grade 2 or 3 Symptoms (Fever, Vomiting or Diarrhoea) — 42 subjects
N/A N=294 Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)
Melanoma
Primary: Number of Participants Who Completed Treatment — 120 Participants
Phase 3 N=147 Safety of New Formulation of Glatiramer Acetate
Relapsing Remitting Multiple Sclerosis
Primary: Subject-reported Pain Associated Immediately After Each Injection — 11.89; 8.64 Scores on a scale
N/A N=502 Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)
Bacterial Infections
Primary: Number of Participants With an Investigator's Assessment of Clinical Outcome (Effective (Cured)/ Not Effective (Not Cured)) at End of the Study. — 438; 19 participants
Phase 4 N=91 Tocilizumab Real-Life Human Factors (RLHFs) Validation Study
Rheumatoid Arthritis
Primary: Percentage of Participants Who Successfully Performed Safety-Critical and Essential Tasks During First Unassisted Use — 100.00; 100.00; 100.00; 100.00 percentage of…